Adverse events following booster doses of diphtheria-tetanus-inactivated poliovirus and acellular pertussis vaccines for 4-year-old children in The Netherlands

Vaccine

Volumn 25, Issue 29, 2007, Pages 5272-5277

  Bults, M ^a   Kemmeren, J M ^a   van der Maas, N A T ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Acellular pertussis vaccine; Diphtheria tetanus inactivated poliovirus vaccine; Extensive limb swelling; Local reactions; Systemic events

Indexed keywords

DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; PERTUSSIS VACCINE;

ARTICLE; DISEASE SEVERITY; DIZZINESS; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNIZATION; INCIDENCE; INJECTION SITE DERMATITIS; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LIMB SWELLING; MAJOR CLINICAL STUDY; MALE; NAUSEA; NETHERLANDS; PALLOR; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SYNCOPE; VOMITING;

CHILD; CHILD, PRESCHOOL; DIPHTHERIA TOXOID; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; MALE; NETHERLANDS; PERTUSSIS VACCINE; POLIOVIRUS VACCINE, INACTIVATED; TETANUS TOXOID; VACCINES, ACELLULAR; VACCINES, COMBINED;

EID: 34347237224     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.017     Document Type: Article

References (29)

1. de Greeff S.C., Schellekens J.F.P., Mooi F.R., and de Melker H.E. Effect van vaccinatie tegen kinkhoest op de incidentie van kinkhoest in Nederland, 1996-2003. Ned Tijdschr Geneeskd 149 17 (2005) 937-943. http://www.ntvg.nl/Jaargangen/2005/PDFa/2005109370001A.pdf
2. Abbink F, de Greeff SC, van den Hof S, de Melker HE. Het Rijksvaccinatieprogramma in Nederland: het vóórkomen van de doelziekten (1997-2002). RIVM rapport nr 210021001/2004. Rijksinstituut voor Volksgezondheid en Milieu. Bilthoven 2004 (http://www.rivm.nl/bibliotheek/rapporten/210021001.pdf).
3. Gezondheidsraad. Wijziging Rijksvaccinatieprogramma; vervroegde vaccinatie. Den Haag; Gezondheidsraad, 1999; publicatienummer 1999/09.
4. de herziene druk. Assen: Koninklijke van Gorcum, 2002.
5. Decker M.D., Edwards K.M., Steinhoff M.C., Rennels M.B., Pichichero M.E., Englund J.A., et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 96 (1995) 557-566
6. Pichichero M.E., Edwards K.M., Anderson E.L., Rennels M.B., Englund J.A., Yerg D.E., et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 105 (2000) 11-19. http://pediatrics.aappublications.org/cgi/content/full/105/1/e11
7. Annunziato P.W., Rothstein E.P., Bernstein H.H., Blatter M.M., Reisinger K.S., and Pichichero M.E. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Arch Pediatr Adolesc Med 148 5 (1994) 503-507
8. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. New Engl J Med 334 (1996) 345-348. http://content.nejm.org/cgi/content/full/334/6/341
9. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., and Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350 9091 (1997) 1569-1577
10. Halperin S.A., Scheifele D., Barreto L., Pim C., Guasparini R., Medd L., et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J 18 9 (1999) 772-779
11. van der Maas NAT, Phaff TAJ, Wesselo C, Džaferagić A, Vermeer-de Bondt PE. Adverse Events Following Immunisation under the National Vaccination Programme of The Netherlands. Number XII-Reports in 2005. RIVM Report nr. 240071003. Rijksinstituut voor Volksgezondheid en Milieu. Bilthoven 2006 (http://www.rivm.nl/bibliotheek/rapporten/240071003.html).
12. Liese J.G., Stojanov S., Zink T.H., Froeschle J., Klepadlo R., Kronwitter A., et al. Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Pediatr Infect Dis J 20 (2001) 981-988
13. Rennels M.B., Deloria M.A., Pichichero M.E., Losonsky G.A., Englund J.A., Meade B.D., et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105 (2000) e1-e12. http://pediatrics.org/cgi/content/full/105/1/e12
14. Woo E.J., Burwen D.R., Gatumu S.N.M., Ball R., and the Vaccine Adverse Event Reporting System (VAERS) Working Group. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System. Clin Infect Dis 37 (2003) 351-358. http://www.journals.uchicago.edu/CID/journal/issues/v37n3/30555/30555.ht ml
15. Rennels M.B. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis 14 3 (2003) 196-198
16. Skowronski D.M., Remple V.P., Macnabb J., Pielak K., Patrick D.M., Halperin S.A., et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity and anticipated impact. Pediatrics 112 (2003) 453-459. http://www.pediatrics.org/cgi/content/full/112/6/e453
17. Keijzer-Veen M.G., Holty-van der Wekken L., Juttmann R.E., de Groot R., and Rümke H.C. Reactogenicity of acellular pertussis vaccine in 4-year-olds in The Netherlands. Vaccine 22 (2004) 3256-3257
18. Gold M.S., Noonan S., Osbourn M., Precepa S., and Kempe A.E. Local reactions after the fourth-dose of acellular pertussis vaccine in South Australia. MJA 179 (2003) 191-194. http://www.mja.com.au/public/issues/179_04_180803/gol10534_fm.html
19. Adverse Drug Reactions Advisory Committee (ADRAC). Extensive limb swelling and DTPa booster doses. Aust Adverse Drug React Bull 20 (2001) 10
20. Marshall H.S., Gold M.S., Gent R., Quinn P.J., Piotto L., Clarke M.F., et al. Ultrasound examination of extensive limb swelling reactions after diphtheria-tetanus-acellular pertussis or reduced-antigen content diphtheria-tetanus-acellular pertussis immunization in preschool-aged children. Pediatrics 118 4 (2006) 1501-1509
21. National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. (2003), Australian Government Publishing Service, Canberra, Australia
22. Pichichero M.E., Deloria M.A., Rennels M.B., Anderson E.L., Edwards K.M., Decker M.D., et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 100 (1997) 772-788
23. Jacquet J.M., Bégué P., Grimprel E., Reinert P., Sandbu S., Silfverdal S.A., et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review. Vaccine 24 (2006) 2440-2448
24. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five dose-series. MMWR Recommendations and Reports 2000;17(49):1-8.
25. Scheifele D.W., Halperin S.A., and Ferguson A.C. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine 19 (2001) 4720-4726
26. Halperin S.A., Scheifele D., Mills E., Guasparini R., Humphreys G., Barreto L., et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine 21 (2003) 2298-2306
27. Blennow M., Granstrom M., and Strandell A. Adverse reactions after diphtheria-tetanus booster in 10-year-old schoolchildren in relation to the type of vaccine given for the primary vaccination. Vaccine 12 5 (1994) 427-430
28. Scheifele D.W., Halperin S.A., Ochnio J.J., Ferguson A.C., and Skowronski D.M. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 24 12 (2005) 1059-1066
29. Halperin S.A., Mills E., Barreto L., Pim C., and Eastwood B.J. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 14 9 (1995) 792-797